Pfizer stops one of two Phase 3 trials for sickle cell drug, still plans to seek approval in 2026

Pfiz­er ter­mi­nat­ed one of two late-stage tri­als for a sick­le cell treat­ment can­di­date from its $5.4 bil­lion ac­qui­si­tion of Glob­al Blood Ther­a­peu­tics in 2022.

The phar­ma gi­ant is still run­ning a sec­ond Phase 3 for the drug, known as in­clacum­ab, a spokesper­son con­firmed Tues­day to End­points News.

A Mon­day up­date to the fed­er­al clin­i­cal tri­als data­base shows that Pfiz­er end­ed a Phase 3 of in­clacum­ab due to “poor ac­cru­al and as­so­ci­at­ed [re­cruit­ment] chal­lenges.” The study en­rolled 72 peo­ple out of an orig­i­nal­ly planned 280, ac­cord­ing to clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.